ArticleBMC cancer2021

AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.

Andrew Oar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.